ReCode Therapeutics
Latest round
- Series B
Last raised
- Sep 2023
Total raised
- $288M
Investors
- 19
About ReCode Therapeutics
Based in the US, ReCode Therapeutics, Inc. is a biotechnology company focused on developing innovative genetic therapies for genetically defined diseases with limited treatment options. ReCode Therapeutics, Inc. specializes in advanced genetic medicines targeting diseases like primary ciliary dyskinesia and cystic fibrosis. on September 29, 2025. The company was co-founded by Daniel Siegwart and Michael Torres.ReCode Therapeutics develops advanced genetic medicines targeting diseases with limited treatment options, specifically primary ciliary dyskinesia and cystic fibrosis. The company focuses on innovative delivery systems that enhance the effectiveness of genetic therapeutics across multiple administration routes. ReCode's products cater to healthcare providers and research institutions in North America and Europe, aiming to improve the lives of patients with rare genetic disorders. ReCode Therapeutics generates revenue through strategic partnerships and collaborations with biopharmaceutical companies and academic institutions, focusing on joint research and development initiatives.S. FDA for cystic fibrosis treatment. Revenue structures include milestone payments and royalties tied to the commercialization of developed therapies, leveraging innovative solutions in genetic medicine. In September 2025, ReCode Therapeutics, Inc. The company plans to introduce new genetic therapies aimed at addressing additional genetic disorders by 2025, while also targeting expansion into European markets to broaden its reach.
Who invested in ReCode Therapeutics
19 investors across 4 rounds
See all investors in ReCode Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ReCode Therapeutics
Who invested in ReCode Therapeutics?
ReCode Therapeutics has 19 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ReCode Therapeutics raised?
ReCode Therapeutics has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did ReCode Therapeutics last raise money?
ReCode Therapeutics's most recent round on record is a Series B, in Sep 2023.
What does ReCode Therapeutics do?
Based in the US, ReCode Therapeutics, Inc.
Where is ReCode Therapeutics headquartered?
ReCode Therapeutics is headquartered in Menlo Park, US.
Which VCs invest in companies like ReCode Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at ReCode Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like ReCode Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.